Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang
Johnson & Johnson stock (NYSE: JNJ) is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk. On Monday, December 15, 2025, JNJ shares traded around the $214 level, brushing the upper end of their recent trading range and extending a rally that has put the healthcare bellwether sharply higher on the year. Investing.com+2MarketScreener+2 What’s moving JNJ today isn’t a single earnings surprise. Instead, it’s a high‑impact regulatory catalyst—a newly granted FDA priority voucher tied to a multiple myeloma regimen—arriving the same